Post hoc analysis of data from three phase III trials of atezolizumab in advanced non–small cell lung cancer finds an association between adverse immune reactions and response to treatment.
#cancerresearch #immunotherapy

https://jamanetwork.com/journals/jamaoncology/fullarticle/2801588?guestAccessKey=48272c89-4305-42d3-ac1b-ad0fc75534aa&utm_source=linkedin_company&utm_medium=social_jamaonc&utm_term=9630909556&utm_campaign=article_alert&linkId=211790589